SK DISCOVERY CO., LTD.
- Korea's only quadrivalent cell-cultured flu vaccine rapidly sent to Myanmar upon the request of emergency relief
- SK Chemicals becomes the "troubleshooter" under the flu epidemic with advanced vaccine production capacity
SK Chemicals delivered an emergency rescue on the global stage with its flu vaccine.
SK Chemicals announced on the 4th that it made an urgent delivery of 'SKYCellflu Quadrivalent,' the world's 1st cell-cultured quadrivalent flu vaccine, to Myanmar, which has seen a spike in deaths from influenza recently.
The provision of SKYCellflu Quadrivalent was made upon the request of the Myanmar government and its neighboring countries to the WHO for emergency relief because of a severe shortage of vaccine and the rapid spread of influenza.
In response to this request for emergency relief made in late July, SK Chemicals provided the Myanmar government and neighboring countries with SKYCellflu Quadrivalent through local partners last month.
Since formal government approval for the importation and distribution of SKYCellflu Quadrivalent was not completed, the Myanmar health authority granted special approval for this vital vaccine to stop the spread of influenza. Taking this support as an opportunity, SK Chemicals will expedite its application for sale of the product in the Myanmar market.
According to the health authority of Myanmar, the country saw around 180 new suspected cases of influenza as of the end of July and the mortality rate was 5.5% for these patients. This is an unprecedented outbreak in Myanmar where the temperature averages 27℃ throughout the year.
Based on the production technology for cell-cultured quadrivalent flu vaccine, which has become successfully commercialized for the 1st time in the world, SK Chemicals is able to rapidly respond to the flu epidemic by reducing the vaccine's production time to less than half that for the existing fertile-egg method. In addition, since the vaccine is produced by a high-tech sterile culture medium, there is no risk of pollution or reactions by those vaccinated who are allergic to eggs.
An official from SK Chemicals stated, "Just a few companies around the world have the technology to produce flu vaccine by culturing cells. We will continue to accomplish our mission to secure people's health by the rapid supply of vaccine under emergency situations like in Myanmar.
SK Chemicals has completed production of 5.35 million doses of vaccine (1 dose = the quantity needed for one vaccination) to be used in Korea at the end of this year and early next year and began supplying products to hospitals and medical centers across the nation last month. The Korean health authority started free vaccinations against influenza for infants and toddlers from 6-59 months old from the 4th.
[PHOTO] SK Chemicals Made Urgent Supply of Quadrivalent Influenza Vaccine to Flu-ridden Myanmar
- SK Chemicals becomes the "troubleshooter" under the flu epidemic with advanced vaccine production capacity
SK Chemicals delivered an emergency rescue on the global stage with its flu vaccine.
SK Chemicals announced on the 4th that it made an urgent delivery of 'SKYCellflu Quadrivalent,' the world's 1st cell-cultured quadrivalent flu vaccine, to Myanmar, which has seen a spike in deaths from influenza recently.
The provision of SKYCellflu Quadrivalent was made upon the request of the Myanmar government and its neighboring countries to the WHO for emergency relief because of a severe shortage of vaccine and the rapid spread of influenza.
In response to this request for emergency relief made in late July, SK Chemicals provided the Myanmar government and neighboring countries with SKYCellflu Quadrivalent through local partners last month.
Since formal government approval for the importation and distribution of SKYCellflu Quadrivalent was not completed, the Myanmar health authority granted special approval for this vital vaccine to stop the spread of influenza. Taking this support as an opportunity, SK Chemicals will expedite its application for sale of the product in the Myanmar market.
According to the health authority of Myanmar, the country saw around 180 new suspected cases of influenza as of the end of July and the mortality rate was 5.5% for these patients. This is an unprecedented outbreak in Myanmar where the temperature averages 27℃ throughout the year.
Based on the production technology for cell-cultured quadrivalent flu vaccine, which has become successfully commercialized for the 1st time in the world, SK Chemicals is able to rapidly respond to the flu epidemic by reducing the vaccine's production time to less than half that for the existing fertile-egg method. In addition, since the vaccine is produced by a high-tech sterile culture medium, there is no risk of pollution or reactions by those vaccinated who are allergic to eggs.
An official from SK Chemicals stated, "Just a few companies around the world have the technology to produce flu vaccine by culturing cells. We will continue to accomplish our mission to secure people's health by the rapid supply of vaccine under emergency situations like in Myanmar.
SK Chemicals has completed production of 5.35 million doses of vaccine (1 dose = the quantity needed for one vaccination) to be used in Korea at the end of this year and early next year and began supplying products to hospitals and medical centers across the nation last month. The Korean health authority started free vaccinations against influenza for infants and toddlers from 6-59 months old from the 4th.
[PHOTO] SK Chemicals Made Urgent Supply of Quadrivalent Influenza Vaccine to Flu-ridden Myanmar
SK Chemicals Co. Ltd. published this content on 04 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 07 September 2017 07:57:01 UTC.
Original documenthttps://www.skchemicals.com/en/prcenter/new_view.asp
Public permalinkhttp://www.publicnow.com/view/118560E3144450899FA3C050CC54739F3E85B45E
